Buy biotech stock Geron for a 70% return in 12 months: Goldman Sachs
Sell-off in Geron Corp (NASDAQ: GERN) over the past three months has created a great buying opportunity, says Corinne Jenkins – a Goldman Sachs analyst.
Geron shares could shoot up to $4.0Copy link to section
Jenkins upgraded the biotech stock to “buy” on Tuesday and tagged on it a price target of $4.0 that suggests about a 70% upside from here.
Her super bullish view on Geron shares is based primarily on “Imetelstat” – the company’s treatment for transfusion-dependent anaemia in patients with lower-risk MDS.
Based on our review of the data, conversations with KOLs, and regulatory precedent, Imetelstat is likely to be approved in this setting, where we estimate $1.5 billion in unadjusted peak sales.
Last month, the Nasdaq-listed firm reported a loss for its second quarter and came in shy of revenue estimates.
Probability of Imetelstat approval is highCopy link to section
Note that the U.S. Food & Drug Administration has already accepted the NDA for Imetelstat.
Are you looking for fast-news, hot-tips and market analysis? Sign-up for the Invezz newsletter, today.
Looking to invest?
Invest and trade CFD stocks, ETFs, digital assets & commodities in minutes with our highest-rated broker.
It is expected to decide on the treatment by June of 2024 – which means the telomerase inhibitor may be available in the United States in the second half of next year. The Goldman Sachs analyst also said in her research note today:
The physicians we spoke with see a very high likelihood of Imetelstat approval … given the efficacy, manageable safety, and degree of unmet need in this population.”
All in all, she likes Geron shares because the risk-to-benefit profile of the said treatment supports approval, she concluded. Jenkins call arrives only a day after Geron Corp said Michelle Robertson will join as its Chief Financial Officer on September 25th.